Business Context and Reporting Period
Company: Thermo Electron Corporation (now Thermo Fisher Scientific Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 27, 2003
Reporting Status: Unaudited interim financial statements. The company changed its fiscal year-end to December 31, effective 2003.
Key Financial Metrics
| Metric (in thousands) | Q3 2003 | Q3 2002 | 9M 2003 | 9M 2002 |
|---|---|---|---|---|
| Revenues | $497,116 | $517,171 | $1,513,726 | $1,517,610 |
| Operating Income | $42,381 | $44,871 | $129,959 | $116,781 |
| Net Income | $48,515 | $39,017 | $138,081 | $222,578 |
| Diluted EPS (Total) | $0.29 | $0.23 | $0.83 | $1.23 |
| Cash & Equivalents | $207,546 | $233,604 | $207,546 | $233,604 |
| Working Capital | $703,500 | $667,800 | $703,500 | $667,800 |
| Long-Term Debt | $223,948 | $451,341 | $223,948 | $451,341 |
Note: Net Income includes significant gains from discontinued operations ($9.5M in Q3; $14.6M in 9M). Income from Continuing Operations was flat at $39.0M for Q3 and declined to $123.5M for 9M 2003 compared to $152.2M in 9M 2002.
Material Changes vs. Prior Period
- Revenue Decline: Q3 revenues decreased 4% ($20.1M) primarily due to lower demand in industrial and semiconductor markets, partially offset by favorable currency translation ($20.2M). Nine-month revenues were essentially flat.
- Restructuring Costs: Net restructuring and other costs increased significantly to $14.3M in Q3 2003 from $6.9M in Q3 2002. This included a $4.7M writedown of a noncore product line in the Optical Technologies segment.
- Debt Reduction: Long-term obligations decreased by approximately $227M year-to-date due to the redemption of $268M in subordinated convertible debentures and repayment of short-term notes.
- Investment Gains: Other income included a $10.3M gain from the sale of Thoratec Corporation shares in Q3 2003. In 2002, gains were driven by FLIR Systems sales ($94.5M in 9M 2002).
- Tax Benefit: The effective tax rate decreased to 25.6% (Q3) and 21.8% (9M) in 2003, largely due to a $9.0M reversal of a valuation allowance on foreign tax credit carryforwards.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management expects to incur an additional $8M - $10M in restructuring costs through the remainder of 2003 and into 2004.
- Market Conditions: Continued downturns in semiconductor and industrial markets are expected to negatively impact revenue comparisons through at least Q4 2003. The Optical Technologies segment faces a severe slowdown.
- Acquisitions: The company agreed to acquire Jouan SA (Life and Laboratory Sciences) for ~110.9M euros, expected to close before year-end. Two smaller acquisitions were completed in October/November 2003.
- Divestitures: Sold the test and measurement business and the molecular beam epitaxy product line in October 2003 for aggregate proceeds of $23.8M.
- Liquidity: Management believes existing cash, investments, and credit facilities are sufficient to meet working capital needs for the next 24 months.
- Risks: Key risks include cyclical industry downturns, intellectual property litigation (specifically a patent suit by the Lemelson Foundation), and the ability to integrate acquired businesses.
Investor Verification Checklist
- Continuing vs. Discontinued Operations: Verify the sustainability of earnings by excluding the $14.6M gain on disposal of discontinued operations from the 9-month Net Income.
- Restructuring Run-Rate: Confirm the timing and cash impact of the remaining $8M-$10M in expected restructuring costs.
- Segment Performance: Review the negative operating margin (-10.3%) in the Optical Technologies segment and the writedown of $4.7M related to the MBE product line.
- Debt Structure: Note the significant reduction in interest-bearing debt and the impact on future interest expense.
- Goodwill Impairment: Assess the $1.44B goodwill balance against the backdrop of cyclical market downturns in key segments.